NeOnc Technologies has developed a proprietary drug-delivery platform that aims to revolutionize the treatment of central nervous system (CNS) diseases, particularly brain cancers. This innovative technology addresses the significant challenge posed by the blood-brain barrier (BBB), which often restricts the effective delivery of therapeutics to the brain. By utilizing their patented methods, NeOnc enables the direct transport of pharmaceutical agents across the BBB, potentially enhancing the efficacy of existing and new treatments for conditions such as glioblastoma. Their approach not only facilitates the delivery of novel therapeutics but also improves the therapeutic outcomes for patients who have previously faced limited options due to delivery challenges.

The company's product pipeline includes NEO100 and NEO212, both of which are currently undergoing clinical trials. NEO100 has shown promising results in improving patient outcomes, while NEO212 is in the Phase 1 clinical trial stage for treating tumor-based brain cancer. NeOnc's commitment to research and development is underscored by their recognition in the medical technology field, including receiving a Breakthrough Medical Technology Achievement Award. Their ongoing studies and clinical trials reflect a strong focus on validating the effectiveness of their delivery systems, with the goal of providing healthcare professionals with advanced tools to improve treatment outcomes for patients suffering from CNS diseases.

United States

NeOnc is the developer of a proprietary, patented platform technology that can potentially transport pharma-based therapeutics directly to the brain without the normal boundary restrictions imposed by the body’s Blood-Brain Barrier (BBB). Using NeOnc’s formulations, pharma companies that have limited success with their CNS therapeutics because of current delivery restrictions may be able to provide patients with potentially more effective treatments.

NEONC Technologies

Company Details